Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth

Digital Impetus Driven By Pandemic Has Long-Lasting Effects

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

Telehealth took a giant leap forward when the COVID-19 pandemic arrived on the scene in early 2020. The need for strict social distancing had an almost overnight effect on access to health care facilities, massively reducing the ability of physicians and nurses to diagnose, treat and monitor patients. Digital tools came into their own and the long-awaited telehealth revolution was turbocharged.

Among the 200+ biopharma executives and experts who looked into their crystal balls to predict the hot topics of the coming year, many flagged up digital

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.